Pfizer said today that the new test results show their coronavirus vaccine is 95% effective, safe and also protects the elderly at the highest risk of death. The new results are part of the final data the company needs to authorize the emergency use of the limited vaccine source.
The vaccine is among the seven vaccines Canada has pre-ordered.
The announcement comes a week after Pfizer first revealed promising preliminary results.
They have also begun submitting vaccines to regulators in Europe, the UK and Canada, and will add this new data soon.
US-based pharmaceutical giant Pfizer, initially estimated its vaccine, developed with German partner BioNTech, was more than 90% effective after 94 cases of infection were listed. With today’s announcement, the company has now amassed 170 infections in the study – and says only eight of them occurred in volunteers who were vaccinated, not a placebo. One in eight people, the company said, became seriously ill.
Dr. Ugur Sahin, CEO and co-founder of BioNTech, told The Associated Press: “This is an extremely strong protective measure.
The company has yet to release detailed data on the study and the results have not been analyzed by independent experts either. Important questions such as how long the protection lasts and whether people need booster medications also need to be identified.
Earlier this week, Moderna, Inc. Also reported that their experimental vaccine appears to be 94.5% effective after an interim analysis of the end-stage study.
Pfizer and BioNTech also said they now have the necessary data on the safety of the vaccines needed to obtain emergency authorization from the US Food and Drug Administration.
The company did not disclose safety details but said no serious vaccine side effects were reported, with the most common problem being fatigued after the second dose of the vaccine, affecting about 4% of the participants.
The study attracted nearly 44,000 people in the United States and five other countries. The trial will continue to collect safe and effective data on volunteers for another two years.
Pfizer and BioNTech said they expect to produce up to 50 million doses of the vaccine globally by 2020 and up to 1.3 billion doses by 2021.
US officials say they expect about 20 million doses of Moderna and Pfizer’s vaccine to be delivered by the end of December. The first shots will be made available to vulnerable groups such as medical staff. healthcare and nursing homes, and people with serious health conditions.
This content is also available in: Tiếng Việt